Publications

The National Medical Products Administration (“NMPA”) promulgated the Provisions on the Supervision and Administration of Drug Market Authorization Holder Implementation of the Main Re­spons­ib­il­ity...

The National Medical Products Administration (“NMPA”) promulgated the Provisions on the Supervision and Administration of Enterprise Implementation of the Main Responsibility of Medical Device Quality...

What’s next? In a world of ever-ac­cel­er­at­ing change, staying ahead of the curve and knowing what’s next for your business or sector is essential. At CMS, we see ourselves not only as your legal advisers but also as your business partners. We work together with you to not only resolve current issues but to anticipate future challenges and innovate to meet them. With our latest publication, CMS Next, our experts will regularly offer you insights into and fresh perspectives on a range of issues that businesses have to deal with – from ESG agendas to restructuring after the pandemic or facing the digital transformation. We will also share with you more about the work that we are doing for our clients, helping them innovate, grow and mitigate risk. To be able to provide you with the best support, we immerse ourselves in your world to understand your legal needs and challenges. However, it is equally important that you know who we are and how we can work with you. So, we invite you to meet our experts and catch a glimpse of what is happening inside CMS. Enjoy reading this publication, which we will update regularly with new content. CMS Executive Team

On 21 April 2022, the Department of Finance of Anhui Province, the Health Commission of Anhui Province and the Healthcare Security Bureau of Anhui Province jointly issued the Circular on Regulating Government...

The National Medical Products Administration ("NMPA") issued the Ad­min­is­trat­ive Provisions on Drug Annual Re­port­ing (“Pro­vi­sions”) on 11 April 2022, which took effect on the same day. The Provisions...

The National Market Supervision Administration adopted the Measures on the Supervision and Administration of Medical Devices Manufacturing (“Measures”) on 10 March 2022, which will take effect as...

The National Market Supervision Administration adopted the Measures on the Supervision and Administration of Medical Devices Trading (“Measures”) on 10 March 2022, which will take effect as of 1...

The National Medical Products Administration ("NMPA") promulgated the newly revised Medical Devices Good Clinical Practice ("New GCP Standard") on 31 March 2022. This New GCP Standard will enter into...

On 24 February 2022, the Supreme People's Court (“SPC”) of the People’s Republic of China (“PRC”) promulgated the In­ter­pret­a­tion on Several Issues Concerning the Application of the General...

On 24 December 2021, the 32nd session of the 13th Standing Committee of the National People's Congress (“NPC”) of the People's Republic of China ("PRC") approved amendments to the PRC Civil Procedure...

The National Medical Products Administration (“NMPA”) promulgated the Regulations on the Supervision and Administration of Cosmetics for Children (“Reg­u­la­tions”) on 30 September 2021. The Regulations...

Welcome to CMS ‘On the Pulse’ video/podcast series for all Life Sciences & Healthcare professionals – legal, compliance, regulatory